The emergence of multidrug-resistant tuberculosis (MDRTB) threatens TB control programs worldwide. Outbreaks of MDRTB in the United States grabbed the attention of the medical community and the general public, and subsequent surveys have found "hot spots" of MDRTB in low- and middle-income countries on four continents. Contributions from experts provide detailed descriptions, causes, molecular biology, laboratory diagnosis, treatment, prevention, and public health aspects of this disease. It gives an authorative overview of MDRTB and should be a useful reference book for clinicians, scientists and other health personnel involved in the care of TB and MDRTB patients in industrialized and developing countries.
1. Introduction: Multidrug-resistant tuberculosis: past, present and future; I. Bastian, F. Portaels. 2. The epidemiology of multidrug-resistant tuberculosis in the United States and other established market economies; M. Moore, E. McCray, I.M. Onorato. 3. Epidemiology of multidrug-resistant tuberculosis in low- and middle-income countries; M.A. Espinal. 4. The interaction of human immunodeficiency virus and multidrug-resistant tuberculosis; E. McCray, I.M. Onorato. 5. Clinical mismanagement and other factors producing antituberculosis drug resistance; A. Pablos-Mendez, K. Lessnau. 6. The molecular mechanisms of drug resistance in mycobacterium tuberculosis; H.E. Takiff. 7. DOTS and multidrug-resistant tuberculosis; M.C. Raviglione. 8.Conventional methods for antimicrobial susceptibility testing of mycobacterium tuberculosis; L. Heifets. 9. Novel rapid antimicrobial susceptibility tests for mycobacterium tuberculosis; J.C. Palomino. 10. Pharmacology of the second-line antituberculosis drugs; C.A. Peloquin, B. Auclair. 11. Treatment of multidrug-resistant tuberculosis; M.D. Iseman, G.A. Huitt. 12. Treatment of multidrug resistant tuberculosis in developing countries; J. Crofton, A. van Deun. 13. Treatment outcome of multidrug-resistant tuberculosis; E.E. Telzak. 14. Chemoprophylaxis and BCG in contacts of multidrug resistant tuberculosis; R.A. Stapledon, R. Lumb, I.S. Lim. 15. Multidrug-resistant tuberculosis and the health care worker; D.M. Weinstock, K.A. Sepkowitz. 16. The development of new chemotherapeutics for multidrug-resistant tuberculosis; C.E. Barry. 17. Population dynamics and control of multidrug-resistant tuberculosis; C. Dye, B.G. Williams. 18.Administrative, engineering, and personal protective measures for controlling mycobacterium tuberculosis; C. Richards, W.R. Jarvis. 19. Making DOTS plus work; P.E. Farmer, S.S. Shin, J. Bayona, J.Y. Kim, J.J. Furin, J.G. Brenner.